PVCT PROVECTUS BIOPHARMACEUTICALS, INC.
Pharmaceutical Preparations · OTC · SEC CIK 315545 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-45.5%
TTM net income YoY-14.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-30.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,575.3%
Net margin-1,615.8%
FCF margin—
EBITDA margin-1,574.8%
Returns
ROE—
ROA-637.5%
ROIC (approx.)—
Asset turnover0.39x
Leverage & solvency
Liabilities / assets1,003.6%
Debt / equity—
Current ratio0.08x
Interest coverage-991.90x
Cash quality & payout
Operating cash flow / net income0.61x
Accruals ratio-247.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $336,108 | $617,140 | $557,710 | $989,042 | — |
| R&D expense | $1.90M | $2.05M | $1.75M | $2.39M | $2.61M |
| SG&A expense | $3.73M | $3.10M | $1.71M | $2.03M | $2.06M |
| Operating income | -$5.29M | -$4.53M | -$2.90M | -$3.43M | -$4.67M |
| Interest expense | $5,338 | $13,591 | $5,650 | $3,409 | $961,702 |
| Pretax income | -$5.51M | -$4.77M | -$3.10M | -$3.55M | -$5.54M |
| Net income | -$5.43M | -$4.73M | -$3.10M | -$3.55M | -$5.54M |
| EBITDA | -$5.29M | -$4.53M | -$2.89M | -$3.42M | -$4.66M |
| EPS (basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS (diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Weighted avg. shares (diluted) | 420.28M | 419.81M | 419.51M | 419.47M | 408.22M |
| Banking | |||||
| Net interest income | -$210,359 | -$239,073 | -$216,214 | -$163,691 | -$961,698 |
| Balance sheet | |||||
| Cash & equivalents | $251,291 | $307,442 | $76,576 | $21,605 | $682,984 |
| Receivables | — | — | $476 | $394 | $5,107 |
| Current assets | $567,874 | $976,772 | $1.36M | $1.90M | $3.44M |
| PP&E, net | $3,000 | $4,863 | $12,020 | $20,941 | $31,836 |
| Total assets | $697,502 | $1.01M | $1.45M | $2.04M | $3.51M |
| Current liabilities | $6.90M | $6.98M | $9.02M | $8.19M | $7.70M |
| Total liabilities | $7.00M | $6.98M | $9.04M | $8.27M | $7.70M |
| Shareholders' equity | -$6.30M | -$5.96M | -$7.59M | -$6.23M | -$4.19M |
| Shares outstanding | 420.28M | 420.28M | 419.52M | 419.45M | 419.45M |
| Cash flow statement | |||||
| Operating cash flow | -$3.33M | -$3.28M | -$2.57M | -$3.04M | -$1.01M |
| Financing cash flow | $3.09M | $2.75M | $2.19M | $1.37M | $4.02M |
| Depreciation & amortization | $1,863 | $7,157 | $8,921 | $10,895 | $12,865 |
| Stock-based compensation | $1.24M | $1.28M | $2,850 | $3,025 | $23,688 |
Free plan shows the latest 5 periods; Pro shows all 24 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.